RESUMO
The unbound concentrations of 14 commercial drugs, including five non-efflux/uptake transporter substrates-Class I, five efflux transporter substrates-class II and four influx transporter substrates-Class III, were simultaneously measured in rat liver, muscle, and blood via microanalysis. Kpuu,liver and Kpuu,muscle were calculated to evaluate the membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver. For Class I compounds, represented by antipyrine, unbound concentrations among liver, muscle and blood are symmetrically distributed when compound hepatic clearance is low. And when compound hepatic clearance is high, unbound concentrations among liver, muscle and blood are asymmetrically distributed, such as Propranolol. For Class II and III compounds, overall, the unbound concentrations among liver, muscle, and blood are asymmetrically distributed due to a combination of hepatic metabolism and efflux and/or influx transporter activity.
Assuntos
Membrana Celular/metabolismo , Fígado/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Músculo Esquelético/metabolismo , Preparações Farmacêuticas/metabolismo , Animais , Antipirina/sangue , Antipirina/metabolismo , Atenolol/sangue , Atenolol/metabolismo , Carbamazepina/sangue , Carbamazepina/metabolismo , Digoxina/sangue , Digoxina/metabolismo , Diltiazem/sangue , Diltiazem/metabolismo , Difenidramina/sangue , Difenidramina/metabolismo , Vias de Eliminação de Fármacos , Gabapentina/sangue , Gabapentina/metabolismo , Lamotrigina/sangue , Lamotrigina/metabolismo , Memantina/sangue , Memantina/metabolismo , Microdiálise , Ofloxacino/sangue , Ofloxacino/metabolismo , Preparações Farmacêuticas/sangue , Propranolol/sangue , Propranolol/metabolismo , Pirilamina/sangue , Pirilamina/metabolismo , Quinidina/sangue , Quinidina/metabolismo , Ratos , Terfenadina/análogos & derivados , Terfenadina/sangue , Terfenadina/metabolismoRESUMO
A sensitive capillary zone electrophoresis (CZE) combined with field-amplified sample injection (FASI) method was investigated to simultaneously determine diltiazem (DI) hydrochloride and metoprolol (ME) tartrate in human serum. This method was validated by linearity, limits of detection (LOD), stability, precision and accuracy, and the related parameters are linearity (r2 > 0.9980), intra- and inter-day precisions (intra-day relative standard deviation (RSD) is 2.3-3.4%, and inter-day RSD is 3.8-7.5%) and the LOD (0.02 ng/mL for ME tartrate and 0.01 ng/mL for DI hydrochloride). So the proposed method is rapid, sensitive and accurate for determination of these two anti-anginal drugs in human serum. As for enrichment conditions, it was helpful to add phosphoric acid and isopropanol into samples for enrichment efficiency. A model was established to illustrate the possible enrichment mechanism of analytes, and a theory of half-width was also applied in CZE combined with FASI method to evaluate the peak performance.
Assuntos
Diltiazem/sangue , Eletroforese Capilar/métodos , Metoprolol/sangue , Humanos , Limite de Detecção , Modelos Lineares , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Therapeutic drug monitoring (TDM) is necessary for the optimal administration of anti-arrhythmic drugs in the treatment of heart arrhythmia. The present study aimed to develop and validate a direct analysis in real time tandem mass spectrometry (DART-MS/MS) method for the rapid and simultaneous determination of five anti-arrhythmic drugs (metoprolol, diltiazem, amiodarone, propafenone, and verapamil) and one metabolite (5-hydroxy(OH)-propafenone) in human serum. After the addition of isotope-labeled internal standards and protein precipitation with acetonitrile, anti-arrhythmic drugs were ionized by DART in positive mode followed by multiple reaction monitoring (MRM) detection. The use of DART-MS/MS avoided the need for chromatographic separation and allowed rapid and ultrahigh throughput analysis of anti-arrhythmic drugs in a total run time of 30 s per sample. The DART-MS/MS method yielded satisfactory linearity (R2 ≥ 0.9906), accuracy (86.1-109.9%), and precision (≤ 14.3%) with minimal effect of biological matrixes. The method was successfully applied to analyzing 30 clinical TDM samples. The relative error (RE) of the concentrations obtained by DART-MS/MS and liquid chromatography-tandem mass spectrometry (LC-MS/MS) was within ± 13%. This work highlights the potential usefulness of DART for the rapid quantitative analysis of anti-arrhythmic drugs in human serum and gives rapid feedback in the clinical TDM practices.
Assuntos
Antiarrítmicos/sangue , Sistemas Computacionais , Monitoramento de Medicamentos/métodos , Preparações Farmacêuticas , Amiodarona/sangue , Antiarrítmicos/uso terapêutico , Cromatografia Líquida de Alta Pressão , Diltiazem/sangue , Humanos , Metoprolol/sangue , Propafenona/sangue , Espectrometria de Massas em Tandem , Verapamil/sangueRESUMO
High-performance liquid chromatography (HPLC) and solid phase micro membrane tip extraction (SPMMTE) methods are developed for the simultaneous analysis of eleven cardiovascular drugs in human plasma. Iron nanoparticles were obtained by the green method, characterized by XRD, FT-IR, TEM, and EDS and utilized in SPMMTE for sample preparation. The mobile phase used was ammonium acetate buffer-methanol-acetonitrile (65:18:17) with a 1.0â¯mL/min flow rate at 260â¯nm detection. Column used was Sunshell C18 150â¯×â¯4.6â¯mm, 2.6⯵m. The values of k, α, and Rs were ranged from 040 to109.22, 1.20 to 2.67 and 1.0 to 26.18. SPMMTE and HPLC methods were fast, reproducible, precise, robust, economic and rugged for analysis of methyldopa, hydrochlorothiazide, prazosin hydrochloride, furosemide, labetalol, propranolol, valsartan, losartan potassium, diltiazem, irbesartan and spironolactone in human plasma. The recoveries (%) of methyldopa, hydrochlorothiazide, prazosin hydrochloride, furosemide, labetalol, propranolol, valsartan, losartan potassium, diltiazem, irbesartan, and spironolactone were 91.0, 85.2, 92.3, 90.4, 90.1, 85.6, 86.6, 86.2, 85.1, 86.6, and 85.7, respectively. These results showed that SPMMTE and HPLC methods can be applied to test the described drugs in several matrices.
Assuntos
Anti-Hipertensivos/sangue , Nanopartículas Metálicas/química , Nanocompostos/química , Adsorção , Cromatografia Líquida de Alta Pressão , Diltiazem/sangue , Furosemida/sangue , Humanos , Hidroclorotiazida/sangue , Irbesartana/sangue , Ferro/química , Labetalol/sangue , Limite de Detecção , Losartan/sangue , Metildopa/sangue , Álcool de Polivinil/química , Prazosina/sangue , Propranolol/sangue , Reprodutibilidade dos Testes , Microextração em Fase Sólida , Espironolactona/sangue , Valsartana/sangueRESUMO
Herein, a 3D hierarchical blossom-like of Montmorillonite-ZnO (MMt/ZnO) micro-hybrids modified sensors have been successfully fabricated as an extraordinarily electrochemical sensor for detecting of the Diltiazem hydrochloride (DZM.HCl). The 3D hierarchical blossom-like of ZnO and series of MMt/ZnO hybrids have been synthesized using different contents of MMt [FMZ1-5] via a hydrogel polymer template method using alginate ions. The effect of incorporation of different contents of MMt on the morphology, surface area of hybrids were investigated using Fourier transform infrared (FTIR), X-ray diffraction (XRD), Field emission scanning electron microscopy (FE-SEM), Energy-dispersive X-ray spectroscopy (EDS), Brunauer-Emmett-Teller (BET) surface area method, and High-resolution transmission electron microscopy (HR-TEM). The obtained hybrid [FMZ3] with 2.0% of MMt presented the most perfect blossom-like morphology and the highest surface area (190.06â¯m2/g) with the lowest resistivity. The hierarchical structure of [FMZ3] reveals nanospheres of ZnO with an average diameter of 5.49â¯nm, which are assembled into nanorods followed by assembling to form a blossom-like shape with the inclusion of MMt peeled layers inside the rod with d-spacing ranges from 1.1-7.4â¯nm. Meanwhile, the implemented modified sensor 1.0% [FMZ3] CPS retained excellent conductivity and electrocatalytic activity as appraised from the cyclic voltammetry (CV) measurements. Consequently, the electrochemical behavior and the oxidation mechanism of DZM.HCl drug has been investigated at the surface of the constructed sensor. Under the optimum operational conditions, the proposed sensor was successfully achieved detection limits 0.177, and 0.21â¯nmol·L-1 of DZM.HCl in a commercial and human biological fluid (Serum samples), respectively. The constructed sensor accomplished an appropriate accuracy and free of obstruction from other ordinarily drug excipients.
Assuntos
Bentonita/química , Diltiazem/análise , Técnicas Eletroquímicas/métodos , Óxido de Zinco/química , Diltiazem/sangue , Humanos , Concentração de Íons de Hidrogênio , Limite de Detecção , Microscopia Eletrônica de Varredura , Microscopia Eletrônica de Transmissão , Nanoestruturas/química , Tamanho da Partícula , Porosidade , Reprodutibilidade dos Testes , Espectrometria por Raios X , Propriedades de SuperfícieRESUMO
In this paper we present an FDA validated method to analyze ten antiarrhythmic drugs (atenolol, bisoprolol, carvedilol, diltiazem, flecainide, lidocaine, metoprolol, propranolol, sotalol and verapamil). A simple and fast sample preparation protocol with protein precipitation followed by ultra performance liquid chromatography (UPLC) for chromatographic separation and mass spectrometric detection applying electrospray ionization (ESI+) and selected reaction monitoring mode (MS/MS) was used. Only 50⯵l plasma sample is needed for the simultaneous quantification of all compounds within a 5â¯min run-to-run analysis time. Sotalol-D6, carvedilol-D5 and verapamil-D6 were used as internal standards. The method was validated according to the FDA guidelines. Correlation coefficients were higher than 0.998 for all compounds. Intra- and interday accuracies were within 15 CV(%) for all analytes. The method is currently successfully applied for routine analysis in our hospital.
Assuntos
Antiarrítmicos/sangue , Espectrometria de Massas em Tandem/métodos , Atenolol/sangue , Bisoprolol/sangue , Carvedilol/sangue , Cromatografia Líquida de Alta Pressão , Diltiazem/sangue , Flecainida/sangue , Ensaios de Triagem em Larga Escala/métodos , Humanos , Lidocaína/sangue , Metoprolol/sangue , Propranolol/sangue , Reprodutibilidade dos Testes , Sotalol/sangue , Espectrometria de Massas por Ionização por Electrospray , Verapamil/sangueRESUMO
Three-dimensional printing (3DP), though developed for nonmedical applications and once regarded as futuristic only, has recently been deployed for the fabrication of pharmaceutical products. However, the existing feeding materials (inks and filaments) that are used for printing drug products have various shortcomings, including the lack of biocompatibility, inadequate extrudability and printability, poor drug loading, and instability. Here, we have sought to develop a filament using a single pharmaceutical polymer, with no additives, which can be multi-purposed and manipulated by computational design for the preparation of tablets with desired release and absorption patterns. As such, we have used hydroxypropyl-methylcellulose (HPMC) and diltiazem, a model drug, to prepare both drug-free and drug-impregnated filaments, and investigated their thermal and crystalline properties, studied the cytotoxicity of the filaments, designed and printed tablets with various infill densities and patterns. By alternating the drug-free and drug-impregnated filaments, we fabricated various types of tablets, studied the drug release profiles, and assessed oral absorption in rats. Both diltiazem and HPMC were stable at extrusion and printing temperatures, and the drug loading was 10% (w/w). The infill density, as well as infill patterns, influenced the drug release profile, and thus, when the infill density was increased to 100%, the percentage of drug released dramatically declined. Tablets with alternating drug-free and drug-loaded layers showed delayed and intermittent drug release, depending on when the drug-loaded layers encountered the dissolution media. Importantly, the oral absorption patterns accurately reproduced the drug release profiles and showed immediate, extended, delayed and episodic absorption of the drug from the rat gastrointestinal tract (GIT). Overall, we have demonstrated here that filaments for 3D printers can be prepared from a pharmaceutical polymer with no additives, and the novel computational design allows for fabricating tablets with the capability of producing distinct absorption patterns after oral administration.
Assuntos
Portadores de Fármacos/administração & dosagem , Derivados da Hipromelose/administração & dosagem , Impressão Tridimensional , Animais , Células CACO-2 , Sobrevivência Celular/efeitos dos fármacos , Diltiazem/administração & dosagem , Diltiazem/sangue , Diltiazem/química , Diltiazem/farmacocinética , Portadores de Fármacos/química , Portadores de Fármacos/farmacocinética , Liberação Controlada de Fármacos , Mucosa Gástrica/metabolismo , Humanos , Derivados da Hipromelose/química , Derivados da Hipromelose/farmacocinética , Absorção Intestinal/efeitos dos fármacos , Mucosa Intestinal/metabolismo , Masculino , Ratos , Ratos Sprague-Dawley , ComprimidosRESUMO
A liquid chromatographic tandem mass spectrometric method for the identification and quantification of 18 cardiovascular drugs was developed in order to evaluate two cases of fatal intoxication involving diltiazem and amlodipine respectively. Samples were simply diluted and centrifuged using a three-steps procedure with methanol, acetonitrile and mobile phase. The method proved to be selective and all the validation parameters fulfilled the acceptance criteria. In particular, linearity was studied in the range limits of quantitation (LOQ)-1,000 ng/mL (LOQ ranging from 0.8 to 33.3 ng/mL for urine and from 0.7 to 41.3 ng/mL for whole blood). The method was successfully applied to two real cases involving diltiazem and amlodipine fatal intoxications, respectively. Though the subject intoxicated by diltiazem did survive several hours after drug intake, central and peripheral blood levels at autopsy were extremely high (23.4 and 13.4 mg/L, respectively); the cause could be due to the formation of a pharmacobezoar that was found in the duodenum and that could have delayed the drug absorption. Moreover, diltiazem showed postmortem redistribution. On the contrary, the amlodipine peripheral blood level in the second case was relatively low (0.17 mg/L), thus confirming that even the uncontrolled intake of a less toxic calcium channel blocker can lead to death. Furthermore, blood samples were analyzed after 2 years of storage at -20°C: both diltiazem and amlodipine showed a significant degradation (70 and 99%, respectively).
Assuntos
Anlodipino/intoxicação , Bloqueadores dos Canais de Cálcio/intoxicação , Diltiazem/intoxicação , Adesão à Medicação , Suicídio , Anlodipino/sangue , Autopsia , Bloqueadores dos Canais de Cálcio/sangue , Causas de Morte , Cromatografia Líquida , Diltiazem/sangue , Overdose de Drogas , Evolução Fatal , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Espectrometria de Massas por Ionização por Electrospray , Espectrometria de Massas em TandemRESUMO
BACKGROUND AND OBJECTIVES: Diltiazem is a benzothiazepine calcium blocker and widely used in renal transplant patients since it improves the level of tacrolimus or cyclosporine A concentration. Several population pharmacokinetic (PopPK) models had been established for cyclosporine A and tacrolimus but no specific PopPK model was established for diltiazem. The aim of the study is to develop a PopPK model for diltiazem in renal transplant recipients and provide relevant pharmacokinetic parameters of diltiazem for further pharmacokinetic interaction study. METHODS: Patients received tacrolimus as primary immunosuppressant agent after renal transplant and started administration of diltiazem 90 mg twice daily on 5th day. The concentration of diltiazem at 0, 0.5, 1, 2, 8, and 12 h was measured by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Genotyping for CYP3A4*1G, CYP3A5*3, and MDR1 3435 was conducted by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). 25 covariates were considered in the stepwise covariate model (SCM) building procedure. RESULTS: One-compartment structural pharmacokinetic model with first-order absorption and elimination was used to describe the pharmacokinetic characteristics of diltiazem. Total bilirubin (TBIL) influenced apparent volume of distribution (V/F) of diltiazem in the forward selection. The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively. CONCLUSION: A PopPK model of diltiazem is established in Chinese renal transplant recipients and it will provide relevant pharmacokinetic parameters of diltiazem for further pharmacokinetic interaction study.
Assuntos
Diltiazem/farmacocinética , Transplante de Rim , Subfamília B de Transportador de Cassetes de Ligação de ATP/genética , Adolescente , Adulto , Anti-Hipertensivos/sangue , Anti-Hipertensivos/farmacocinética , Povo Asiático/genética , Citocromo P-450 CYP3A/genética , Diltiazem/sangue , Feminino , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Polimorfismo de Fragmento de Restrição/genética , Tacrolimo/uso terapêutico , Adulto JovemRESUMO
The aim of this study was to prepare and evaluate in vitro and in vivo; Diltiazem-Hydrochloride (DTZ) in sustained-release matrix tablets. Stability of DTZ tablets prepared with polyethylene oxide (MWs 900 000, 4 000 000, and 8 000 000) with or without addition of electrolytes was carried-out for 1-month, under short-term storage at 40 °C/75% RH. Stability was evaluated by DTZ content, DSC and drug release using the Flow-Through Cell (USP # IV). The majority of stored tablets were stable for 1-month under short-term storage with respect to DTZ content and drug release. DSC curves of stored samples showed appearance of new exothermic peak after 1-month storage at 40 °C/75% RH, which was not observed after 5 years storage at room temperature. A selected formula was tested in vivo against reference product on eight healthy human volunteers. DTZ-plasma profiles were different between the two formulae. However, no statistically significant differences were detected between Cmax, AUC0-48 and AUC0-∞. The two products were therapeutically in-equivalent, as 90% confidence intervals "T/R" were 88.82-205.76, 91.40-139.94, and 93.73-134.97 for Cmax, AUC0-48 and AUC0-∞, respectively. This study highlighted possible differences observed between the two regimes frequently applied for stability testing.
Assuntos
Anti-Hipertensivos/sangue , Anti-Hipertensivos/farmacologia , Diltiazem/sangue , Diltiazem/farmacologia , Polietilenoglicóis/metabolismo , Polietilenoglicóis/farmacologia , Adulto , Anti-Hipertensivos/química , Disponibilidade Biológica , Estudos Cross-Over , Diltiazem/química , Estabilidade de Medicamentos , Humanos , Masculino , Pessoa de Meia-Idade , Polietilenoglicóis/química , Solventes/química , Solventes/metabolismo , Solventes/farmacologia , Comprimidos , Adulto JovemRESUMO
Diltiazem is a human therapeutic drug and a member of the group of calcium channel blockers having widespread use in the treatment of angina pectoris and hypertension. The objective of the present study was to assess the bioconcentration, metabolism, and half-life time of diltiazem in rainbow trout Oncorhynchus mykiss. Juvenile trout were exposed for 21 and 42 days to three nominal concentrations of diltiazem: 0.03 µg L(-1) (environmentally relevant concentration), 3 µg L(-1), and 30 µg L(-1) (sub-lethal concentrations). The bioconcentration factor (BCF) of diltiazem was relatively low (0.5-194) in analysed tissues, following the order kidney > liver > muscle > blood plasma. The half-life of diltiazem in liver, kidney, and muscle was 1.5 h, 6.2 h, and 49 h, respectively. The rate of metabolism for diltiazem in liver, kidney, muscle, and blood plasma was estimated to be 85 ± 9%, 64 ± 14%, 46 ± 6%, and 41 ± 8%, respectively. Eight diltiazem metabolites were detected. The presence of desmethyl diltiazem (M1), desacetyl diltiazem (M2), and desacetyl desmethyl diltiazem (M3) suggests that rainbow trout metabolize diltiazem mainly via desmethylation and desacetylation, similar to mammals. In addition, diltiazem undergoes hydroxylation in fish. At environmentally relevant concentrations, diltiazem and its metabolites were identified in liver and kidney, indicating the potential for uptake and metabolism in non-target organisms in the aquatic environment.
Assuntos
Diltiazem/farmacocinética , Oncorhynchus mykiss/metabolismo , Poluentes Químicos da Água/farmacocinética , Animais , Diltiazem/sangue , Meia-Vida , Rim/metabolismo , Fígado/metabolismo , Músculos/metabolismo , Poluentes Químicos da Água/sangueRESUMO
AIM: Co-administration of diltiazem can reduce the dosage of cyclosporine (CsA) in patients with renal transplantation. In this study, we investigated how diltiazem altered the relationship between MDR1 genetic polymorphisms and CsA concentration in Chinese patients with renal transplantation. METHODS: A total of 126 renal transplant patients were enrolled. All the patients received CsA (2-4 mg·kg(-1)·d(-1)), and diltiazem (90 mg/d) was co-administered to 76 patients. MDR1-C1236T, G2677T/A, and C3435T polymorphisms were genotyped. The whole blood concentration was measured using the FPIA method, and the adjusted trough concentrations were compared among the groups with different genotypes. RESULTS: In all patients, MDR1-C1236T did not influence the adjusted CsA trough concentration. With regard to MDR1-3435, the adjusted CsA trough concentration was significantly higher in TT carriers than in CC and CT carriers when diltiazam was co-administered (58.83±13.95 versus 46.14±7.55 and 45.18±12.35 ng/mL per mg/kg, P=0.011), and the differences were not observed in patients without diltiazam co-administered. With regard to MDR1-2677, the adjusted CsA trough concentration was significantly higher in TT carriers than in GG and GT carriers when diltiazam was co-administered (61.31±12.93 versus 52.25±7.83 and 39.70±7.26 ng/mL per mg/kg, P=0.0001). The differences were also observed in patients without diltiazam co-administered (43.27±5.95 versus 35.22±7.55 and 29.54±5.35 ng/mL per mg/kg, P=0.001). The adjusted CsA trough blood concentration was significantly higher in haplotype T-T-T and haplotype T-T-C carriers than in non-carriers, regardless of diltiazem co-administered. CONCLUSION: MDR1 variants influence the adjusted CsA trough concentration in Chinese patients with renal transplant, and the influence more prominent when diltiazem is co-administered.
Assuntos
Povo Asiático/genética , Ciclosporina/administração & dosagem , Diltiazem/administração & dosagem , Genótipo , Transplante de Rim , Subfamília B de Transportador de Cassetes de Ligação de ATP/genética , Adolescente , Adulto , Idoso , Inibidores de Calcineurina/administração & dosagem , Inibidores de Calcineurina/sangue , Ciclosporina/sangue , Diltiazem/sangue , Sinergismo Farmacológico , Quimioterapia Combinada , Feminino , Humanos , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único/genética , Adulto JovemRESUMO
A novel micellar per aqueous liquid chromatographic method was investigated to simultaneously determine diltiazem hydrochloride, metoprolol tartrate and isosorbide mononitrate in human serum. Separation and determination of the analytes were performed on a Pinnacle II Cyano column as the stationary phase using the mobile phase consisted of aqueous solution (4.15×10(-2) mol/L sodium dodecyl sulfate and 0.02 mol/L sodium dihydrogen phosphate) with 10% (v/v) of 1-propanol at pH 7.0. This method was validated by linearity, lower limit of quantification, extraction recovery, stability, precision, and accuracy. The main analytical parameters were linearity (r>0.9950), intra- and inter-day precisions (intra-day RSD 2.2-3.5%, and inter-day RSD 3.7-9.5%), lower limit of quantification (20 ng mL(-1) for isosorbide mononitrate, metoprolol tartrate and diltiazem hydrochloride). The extraction recovery was 63.3% (0.1 µg/mL), 65.6% (1.0 µg/mL), and 69.5% (25 µg/mL) for isosorbide mononitrate; 65.1% (0.1 µg/mL), 69.5% (1.0 µg mL) and 73.5% (2.5 µg/mL) for metoprolol tartrate; 67.1% (0.1 µg/mL), 68.8% (1.0 µg/mL) and 73.8 % (2.5 µg/mL) for diltiazem hydrochloride. The relative error of stability was <6.4% at the room temperature for 24h, <3.8% at 4 °C for 1 week, <4.6% at -20 °C for 1 month, and <6.7% for freeze/thaw cycles (n=3). The results indicated that the proposed method was rapid, sensitive, and accurate for determination of the three antianginal drugs in human serum. The possible separation mechanism of the method was also discussed, and a model of separation mechanism for the analytes was established.
Assuntos
Cromatografia Líquida/métodos , Diltiazem/sangue , Dinitrato de Isossorbida/análogos & derivados , Metoprolol/sangue , Diltiazem/química , Estabilidade de Medicamentos , Humanos , Concentração de Íons de Hidrogênio , Dinitrato de Isossorbida/sangue , Dinitrato de Isossorbida/química , Modelos Lineares , Metoprolol/química , Micelas , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Typically, colonic absorption of a drug is mandatory for a sustained release formulation to hold the drug's plasma level for more than 12 or 24 h above the minimum therapeutic plasma concentration (efficacy). According to Drugs@FDA, only 7.4% of the oral drugs are extended release forms probably showing colonic absorption. Therefore an early determination of a drug's colonic absorption using the IntelliCap® in animals or humans will provide the mandatory information to initiate or stop a SR form development. Diltiazem (60 mg) is used in the oral swallowable IntelliCap® and the marketed SR form from Mylan (coated beads). A human study with 14 healthy volunteers compared the Mylan formulation with the IntelliCap® device that releases the drug identical to the in-vitro dissolution of the Mylan product. The plasma profiles of IntelliCap® and Mylan formulation are highly similar. The mean AUC (bioequivalence fulfilled) and mean Cmax of IntelliCap® shows only a difference of +15% and -12%, respectively. But the PK profile of the Mylan formulation shows a broader peak around Cmax. About 81.8% diltiazem was absorbed in the colon (IntelliCap®) comparable to former publications. The Mylan is a SR diffusion coated beads form whereas the IntelliCap® is a monolithic capsule. The beads are transported in the gut and spread which results in a longer Tmax and a broader Cmax peak. The IntelliCap® device can quantitatively measure the colonic absorption of a drug in excellent accordance to a standard oral SR dosage form.
Assuntos
Colo/metabolismo , Diltiazem/administração & dosagem , Diltiazem/farmacocinética , Absorção Intestinal , Administração Oral , Adulto , Área Sob a Curva , Disponibilidade Biológica , Cápsulas , Estudos Cross-Over , Preparações de Ação Retardada , Diltiazem/sangue , Diltiazem/química , Desenho de Equipamento , Trânsito Gastrointestinal , Humanos , Masculino , Taxa de Depuração Metabólica , Solubilidade , Transdutores , Adulto JovemRESUMO
Drug-drug interactions between topiramate and diltiazem, hydrochlorothiazide, or propranolol were evaluated along with safety/tolerability in three open-label studies. Healthy participants (aged 18-45 years) received topiramate 75 mg every 12 hours (q12h) and diltiazem 240 mg/day (study 1); topiramate 96 mg q12h and hydrochlorothiazide 25 mg/day (study 2); topiramate 100 mg q12h and propranolol 40-80 mg q12h (study 3). The pharmacokinetic parameters for topiramate, diltiazem (and active metabolites, desacetyldiltiazem [DEA], N-demethyl diltiazem [DEM]), hydrochlorothiazide, and propranolol (and its active metabolite) were assessed at steady state. Results showed no effect of diltiazem on topiramate pharmacokinetics. However, a modest reduction in systemic exposures of diltiazem and DEA (10-27%) occurred during coadministration with topiramate. Systemic exposure of DEM was unaffected. Furthermore, oral and renal clearance of topiramate decreased (22-30%) significantly (P < 0.05) during coadministration with hydrochlorothiazide, while systemic exposure increased by 27-29%. Topiramate had no effect on hydrochlorothiazide pharmacokinetics. The results demonstrated lack of pharmacokinetic interaction between topiramate and propranolol. Overall, no new safety concerns emerged when topiramate was coadministered with diltiazem, hydrochlorothiazide, or propranolol.
Assuntos
Diltiazem/farmacocinética , Frutose/análogos & derivados , Hidroclorotiazida/farmacocinética , Propranolol/farmacocinética , Adolescente , Adulto , Área Sob a Curva , Biotransformação , Diltiazem/administração & dosagem , Diltiazem/efeitos adversos , Diltiazem/sangue , Esquema de Medicação , Interações Medicamentosas , Monitoramento de Medicamentos/métodos , Feminino , Frutose/administração & dosagem , Frutose/efeitos adversos , Frutose/sangue , Frutose/farmacocinética , Meia-Vida , Voluntários Saudáveis , Humanos , Hidroclorotiazida/administração & dosagem , Hidroclorotiazida/efeitos adversos , Hidroclorotiazida/sangue , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Propranolol/administração & dosagem , Propranolol/efeitos adversos , Propranolol/sangue , Topiramato , Estados Unidos , Adulto JovemRESUMO
This study investigated the effect of piperine on the gene expression of P-glycoprotein (P-gp) as well as pregnane-X-receptor (PXR) activity and also its implication on the bioavailability of diltiazem, a P-gp substrate. The effect of piperine on the systemic exposure of diltiazem was examined in rats after the intravenous and oral administration of diltiazem with/without 2 week pretreatment with piperine. Compared with the control group given diltiazem (20 mg/kg) alone, the pretreatment with piperine (10 or 20 mg/kg, once daily for 2 weeks) decreased the oral exposure of diltiazem by 36-48% in rats. Consequently, the bioavailability of oral diltiazem was significantly lower (p < 0.05) after the 2 week pretreatment with piperine. The pretreatment with piperine for 2 weeks also reduced the systemic exposure of desacetyldiltiazem, a major active metabolite of diltiazem by approximately 73%, accompanied by a significant decrease in the metabolite-parent ratio. In contrast to the oral pharmacokinetics, piperine did not affect the intravenous pharmacokinetics of diltiazem in rats. Immunoblot analysis indicated that the protein expression level of intestinal P-gp was significantly enhanced after the 2 week pretreatment with piperine in rats. In addition, piperine increased the PXR reporter activity in human hepatoma cells. Taken together, the 2 week pretreatment with piperine significantly induced intestinal P-gp expression in conjunction with stimulated PXR activity and decreased the oral exposure of diltiazem and desacetyldiltiazem in rats.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Alcaloides/administração & dosagem , Benzodioxóis/administração & dosagem , Bloqueadores dos Canais de Cálcio/farmacocinética , Diltiazem/farmacocinética , Piperidinas/administração & dosagem , Alcamidas Poli-Insaturadas/administração & dosagem , Receptores de Esteroides/metabolismo , Animais , Disponibilidade Biológica , Bloqueadores dos Canais de Cálcio/sangue , Diltiazem/análogos & derivados , Diltiazem/sangue , Diltiazem/metabolismo , Interações Alimento-Droga , Expressão Gênica/efeitos dos fármacos , Células Hep G2 , Humanos , Masculino , Receptor de Pregnano X , Ratos , Ratos Sprague-DawleyAssuntos
Anti-Hipertensivos/intoxicação , Diltiazem/intoxicação , Acidose Láctica/terapia , Doença Aguda , Idoso , Anti-Hipertensivos/sangue , Anti-Hipertensivos/toxicidade , Preparações de Ação Retardada , Diltiazem/sangue , Diltiazem/toxicidade , Overdose de Drogas/terapia , Feminino , Hemodinâmica , Humanos , VasoplegiaRESUMO
We describe 3 patients admitted to the medical-surgical ICU in a university hospital with life-threatening cardiogenic shock after the ingestion of high doses of calcium channel blockers (8.4 g sustained-release diltiazem, 4.2 g sustained-release diltiazem, and 14.4 g slow-release verapamil). Cardiovascular failure and cardiac conduction disturbances were unresponsive to the usual therapy (eg, intravenous injection of high doses of calcium, glucagon, hyperinsulinemia-euglycemia therapy, fluid resuscitation) and to increasing doses of simultaneous infusions of adrenergic agonists. Albumin dialysis with Molecular Adsorbents Recirculating System (MARS) therapy was performed because of its unique ability to selectively remove from circulation protein-bound toxins (and potentially drugs) that are not cleared by conventional hemodialysis. A single procedure was successfully performed in each patient, which was followed by rapid weaning of adrenergic agonist agents and full recovery of the life-threatening cardiovascular failure. At 2-year follow-up, patients were asymptomatic. Albumin dialysis with MARS therapy may be effective when used as a rescue procedure in patients presenting with sustained, life-threatening cardiogenic shock as a result of massive calcium channel blocker poisoning.
Assuntos
Bloqueadores dos Canais de Cálcio/intoxicação , Diltiazem/intoxicação , Diálise Renal , Choque Cardiogênico/induzido quimicamente , Verapamil/intoxicação , Adolescente , Albuminas/uso terapêutico , Bloqueadores dos Canais de Cálcio/sangue , Preparações de Ação Retardada , Diltiazem/sangue , Overdose de Drogas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Diálise Renal/métodos , Choque Cardiogênico/terapia , Verapamil/sangueRESUMO
Establishment of in vitro-in vivo correlation (IVIVC) accelerates optimization of desirable drug formulations and/or modification of the manufacturing processes in the scale-up and post-approval periods. This article presents a method of finding the optimal conversion function for establishing Level A point-to-point IVIVC, based on a computer-based evolutionary search technique. Gene expression programming (GEP) is a technique for optimizing a mathematical expression tree with the help of a genetic algorithm. A parameter optimization routine, which minimizes the number of parameters in the mathematical expression trees and estimates the best-fit parameter values, was implemented in the GEP algorithm. Feasibility of the computer program was investigated using the in vitro and in vivo data for sustained release diltiazem formulations. It provided a mathematical equation that, from their in vitro dissolution profiles, successfully predicts the plasma concentration profiles of three different formulations of diltiazem following oral administration. Because the present approach does not use intravenous injection data like conventional IVIVC analyses, it is widely applicable to the evaluation of various oral formulations.
Assuntos
Biologia Computacional/métodos , Cálculos da Dosagem de Medicamento , Drogas em Investigação/administração & dosagem , Modelos Biológicos , Farmacogenética/métodos , Farmacologia Clínica/métodos , Administração Oral , Teorema de Bayes , Biotransformação , Química Farmacêutica , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/análise , Preparações de Ação Retardada/química , Preparações de Ação Retardada/farmacocinética , Diltiazem/administração & dosagem , Diltiazem/sangue , Diltiazem/química , Diltiazem/farmacocinética , Drogas em Investigação/análise , Drogas em Investigação/química , Drogas em Investigação/farmacocinética , Estudos de Viabilidade , Regulação da Expressão Gênica , Humanos , Dinâmica não Linear , Software , SolubilidadeRESUMO
Simple, sensitive, rapid, and accurate high-performance liquid chromatographic (HPLC) method is developed and validated for the simultaneous determination of diltiazem, metformin, pioglitazone, and rosiglitazone hydrochloride in raw materials, their pharmaceutical formulations, and human serum. In HPLC, all the above drugs were chromatographed using acetonitrile-methanol-water (30:20:50, v/v, pH 2.59 ± 0.02) as the mobile phase at a flow rate of 1.0 mL/min at ambient temperature. The separation is carried out on a Hiber, 250-4.6 RP-18 column, equipped with a UV-vis detector at 230 nm. All the antidiabetic drugs eluted at different retention time and each showed a good resolution from diltiazem. The method is successfully applied to pharmaceutical formulations because no chromatographic interferences from the tablet excipients are found. The method is found to be linear, accurate, and precise with apposite detection and quantification limit. Suitability of the method for the quantitative determination of the drugs is proven by validation in accordance with the requirements laid down by International Conference on Harmonization (ICH) guidelines. The validation results, together with statistical treatment of the data, demonstrated the reliability of this method.